<DOC>
	<DOCNO>NCT00918333</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose panobinostat everolimus give together see well work treat patient multiple myeloma , non-Hodgkin lymphoma , Hodgkin lymphoma come back . Panobinostat everolimus may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Panobinostat Everolimus Treating Patients With Recurrent Multiple Myeloma , Non-Hodgkin Lymphoma , Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerated dos ( MTD ) LBH589 ( panobinostat ) RAD001 ( everolimus ) use combination patient myeloma lymphoma . ( Phase I ) II . To evaluate therapeutic activity combination LBH589 RAD001 patient relapse refractory lymphoma . ( Arm A , phase II ) III . To evaluate therapeutic activity combination LBH589 RAD001 patient relapse refractory multiple myeloma . ( Arm B , phase II ) SECONDARY OBJECTIVES : I . To describe toxicity associate combination LBH589 RAD001 . ( Phase I ) II . To describe toxicity associate combination LBH589 RAD001 arm independently . ( Phase II ) III . To evaluate overall survival , progression-free survival , duration response arm independently . ( Phase II ) TERTIARY OBJECTIVES : I . To evaluate pharmacokinetic interaction LBH589 RAD001 . II . To assess correlation clinical ( toxicity and/or tumor response activity ) effect pharmacologic ( pharmacokinetic/pharmacodynamic ) parameter , and/or biologic ( correlative laboratory ) result . OUTLINE : This phase I , dose-escalation study panobinostat everolimus follow phase II study . ( dose-escalation close accrual April 6 , 2011 ) Patients receive panobinostat orally ( PO ) daily ( QD ) day 1 , 3 , 5 , 15 , 17 , 19 everolimus PO QD day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Relapsed refractory multiple myeloma require therapy , fail , unable tolerate , refuse available active therapy Biopsyproven relapse refractory nonHodgkin lymphoma Hodgkin disease require treatment , fail , unable tolerate , refuse available active therapy ; patient treatment option consider curative ; ( NOTE : patient lymphoma , rebiopsy necessary unless patient previous biopsy &lt; 6 month prior treatment protocol intervene treatment ; patient biopsyproven central nervous system [ CNS ] lymphoma time require rebiopsy eligible study ) Multiple myeloma : Serum monoclonal protein &gt; = 1.0 g/dL &gt; = 200 mg monoclonal protein urine 24 hour electrophoresis Serum immunoglobulin free light chain &gt; = 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis &gt; = 30 % ( evaluable disease ) time registration Lymphoma : Measurable disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) CT portion positron emission tomography ( PET ) /CT ; must least one lesion single diameter &gt; = 2 cm tumor cell blood &gt; = 5 x 10^9/L ; skin lesion use area &gt; = 2 cm least one diameter photograph ruler The following disease type eligible : Transformed lymphoma Diffuse large B cell lymphoma Mantle cell lymphoma Follicular lymphoma grade III Precursor B lymphoblastic leukemia/lymphoma Mediastinal ( thymic ) large Bcell lymphoma Burkitt lymphoma/leukemia Precursor Tlymphoblastic leukemia/lymphoma Primary cutaneous anaplastic large cell lymphoma Anaplastic large cell lymphoma primary systemic type Small lymphocytic lymphoma/chronic lymphocytic leukemia Follicular lymphoma , grade 1 , 2 Extranodal marginal zone Bcell lymphoma mucosaassociated lymphoid tissue ( MALT ) type Nodal marginal zone Bcell lymphoma Splenic marginal zone Bcell lymphoma Peripheral T cell lymphoma , unspecified . Anaplastic large cell lymphoma ( T null cell type ) Lymphoplasmacytic lymphoma ( Waldenstrom Macroglobulinemia ) CNS lymphoma Post transplant lymphoproliferative disorder Mycosis fungoides/Sezary syndrome Hodgkin Disease Primary effusion lymphoma Blastic natural killer ( NK ) cell lymphoma Adult Tcell leukemia/lymphoma Extranodal NK/Tcell lymphoma , nasal type Enteropathytype Tcell lymphoma Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Angioimmunoblastic Tcell lymphoma Anaplastic large cell lymphoma primary cutaneous type For lymphoplasmacytic lymphoma patient without measurable lymphadenopathy , measurable disease define follow criterion : Bone marrow lymphoplasmacytosis &gt; 10 % lymphoplasmacytic cell aggregate , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy Quantitative immunoglobulin ( Ig ) M monoclonal protein &gt; 1,000 mg/dL Absolute neutrophil count ( ANC ) &gt; = 1000/uL Hemoglobin ( Hgb ) &gt; = 9 g/dl Platelets ( PLT ) &gt; = 75,000/uL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) total bilirubin &gt; 1.5 x ULN direct bilirubin must normal Aspartate aminotransferase ( AST ) = &lt; 3 x ULN Creatinine = &lt; 2.5 x ULN Serum potassium , magnesium phosphorus &gt; = low limit normal ( LLN ) = &lt; 1.2 x ULN Ionized calcium &gt; = LLN Thyroidstimulating hormone ( TSH ) = &lt; 1.5 x ULN ; patient permit receive thyroid hormone supplement treat underlying hypothyroidism Ability understand willingness sign write informed consent document Willingness return Mayo Clinic National Cancer Institute , National Institutes Health ( NIH ) Medical Oncology Branch , Center Cancer Research ( CCR ) Life expectancy &gt; = 12 week Willing provide blood sample research study require protocol Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Candidate know standard therapy patient 's disease potentially curative Uncontrolled infection Therapy myelosuppressive chemotherapy biologic therapy &lt; 3 week unless patient recover nadir previous treatment level meet inclusion eligibility criterion protocol ; NOTE : patient receive prior RAD001 therapy allow must meet requirement Receiving corticosteroid &gt; 20 mg prednisone per day ( equivalent ) ; NOTE : patient may receive stable ( increase within last month ) chronic dos corticosteroids maximum dose 20 mg prednisone per day give disorder lymphoma ( exception CNS lymphoma , steroid permit low possible dose necessary escalate treatment ) rheumatoid arthritis , polymyalgia rheumatica adrenal insufficiency , asthma Persistent toxicity &gt; = grade 2 prior chemotherapy biological therapy regardless interval since last treatment Impaired cardiac function clinically significant cardiac disease , include one following : Patients congenital long QT syndrome History presence sustain ventricular tachyarrhythmia ; ( patient history atrial arrhythmia eligible discuss Sponsor prior enrollment ) Any history ventricular fibrillation torsade de pointes Bradycardia define heart rate ( HR ) &lt; 50 beat per minute ( bpm ; ) patient pacemaker eligible HR &gt; = 50 bpm Screening electrocardiogram ( ECG ) QTcFredericia ( QTcF ) &gt; 450 msec Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina = &lt; 6 month prior start study drug Other clinically significant heart disease ( e.g. , congestive heart failure [ CHF ] New York [ NY ] Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Any follow : Pregnant woman woman reproductive ability unwilling use effective contraception Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 4 week stop treatment Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) ; NOTE : patient may undergo palliative concurrent radiation myeloma lesion pain control impending fracture , provide lesion ( ) constitute progression Known positivity human immunodeficiency virus ( HIV ) hepatitis C uncontrolled disease ; baseline test HIV require ; Note : detailed assessment Hepatitis B/C medical history risk factor must do screening patient ; hepatitis b virus ( HBV ) deoxyribonucleic acid ( DNA ) hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) polymerase chain reaction ( PCR ) test require screening patient positive medical history base risk factor and/or confirmation prior HBV infection Active malignancy require treatment would interfere assessment response lymphoma myeloma protocol treatment Inability swallow impairment gastrointestinal function gastrointestinal disease may significantly alter absorption drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) would preclude use oral medication Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Any severe and/or uncontrolled medical condition condition , treat physician 's opinion , could adversely impact ability participate study ; NOTE : patient chronic oxygen therapy , liver disease cirrhosis , chronic hepatitis chronic persistent hepatitis , uncontrolled infection exclude Known hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) Receiving medication substance strong moderate inhibitor CYP3A4 ; receive medication substance inducer CYP3A4 Using medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Active bleeding tendency ; NOTE : patient therapeutic anticoagulation monitor carefully maintain therapeutic level anticoagulation avoid increase risk bleeding due concurrent drug induce thrombocytopenia ; suggest patient require anticoagulation therapy therapy use low molecular weight heparin ( LMWH ) Major surgery = &lt; 4 week prior registration recover side effect therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>